Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LEGN
#1525
Legend Biotech Corporation American Depositary Shares
20.520
0
USD
+9.79%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+9.79%
Monthly Change
+8.74%
6 month change
-35.83%
Year Change
-35.83%
Previous Close
18.690
0
Open
20.520
0
Bid
Ask
Low
20.520
0
High
20.520
0
Volume
91
Markets
US Stock Market
Healthcare
LEGN
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q4, 24
Q4, 25
TTM
Key stats
Total common shares outstanding
183.65 M
184.94 M
715.57 M
Valuation ratios
Enterprise value
5.98 B
4.02 B
28.79 B
Price to earnings ratio
—
—
—
Price to sales ratio
—
—
—
Price to cash flow ratio
—
—
—
Price to book ratio
—
—
—
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
—
—
—
Return on equity %
—
—
—
Return on invested capital %
—
—
—
Gross margin %
—
—
—
Operating margin %
—
—
—
EBITDA margin %
—
—
—
Net margin %
—
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
—
—
—
Inventory turnover
—
—
—
Asset turnover
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
—
—
—
Net current asset value per share
—
—
—
Tangible book value per share
—
—
—
Working capital per share
—
—
—
Book value per share
—
—
—
News
Germany stocks lower at close of trade; DAX down 1.59%
RBC Capital lowers Legend Biotech stock price target on model updates
Raymond James reiterates Legend Biotech stock rating on strong Q4 results
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity
Jefferies reiterates Legend Biotech stock rating on Carvykti sales
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales
Legend Bio earnings matched, revenue fell short of estimates
Legend Biotech Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LEGN) 2026-03-10
Legend Biotech earnings on deck as profitability looms
Raymond James reiterates Legend Biotech stock rating after rival approval
European stocks edge lower; ongoing Middle East conflict saps confidence
These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.